The clinical application of a urine albumin:creatinine ratio point-of-care device

Bernard Lewis Croal, William James Mutch, A. Dickie, J. Church, I. S. Ross, B. M. Clark, D. Noble

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Introduction: Microalbuminuria is an accepted predictive marker for the early detection of renal disease and the identification of patients at high risk of developing complications of diabetes and hypertension. The Bayer Clinitek 50 is a urine chemistry point-of-care analyser for the semi-quantitative measurement of albumin and creatinine and calculation of albumin:creatinine ratio (ACR). Method: Urine samples were obtained from 252 consecutive patients attending a city center diabetic clinic, and from 40 patients on admission to the ICU. Albumin and creatinine measurements were carried out using the Clinitek 50 and by the central laboratory. Results: The Clinitek 50 results agreed with the central laboratory results in 89% of the diabetic patient samples and 80% of the ICU patient samples. Excluding samples defined as normal by the Clinitek 50 (ACR < 3.4 mg/mmol) would have resulted in an 80% reduction in samples sent to the lab for further quantification. The average length of stay in the group of ICU patients with normal ACR was significantly less than for those patients with an abnormal ACR (p < 0.005). Conclusions: The Clinitek 50 provides useful, immediate clinical information regarding the microalbuminuria status for use in the diabetic clinic setting or as a potential immediate risk management tool in intensive care. (C) 2001 Elsevier Science B.V. All rights reserved.

    Original languageEnglish
    Pages (from-to)15-21
    Number of pages6
    JournalClinica Chimica Acta
    Volume307
    Issue number1-2
    DOIs
    Publication statusPublished - 2001

    Keywords

    • microalbuminuria
    • diabetes mellitus
    • intensive care
    • MICROALBUMINURIA
    • DISEASE

    Cite this

    Croal, B. L., Mutch, W. J., Dickie, A., Church, J., Ross, I. S., Clark, B. M., & Noble, D. (2001). The clinical application of a urine albumin:creatinine ratio point-of-care device. Clinica Chimica Acta, 307(1-2), 15-21. https://doi.org/10.1016/S0009-8981(01)00450-8

    The clinical application of a urine albumin:creatinine ratio point-of-care device. / Croal, Bernard Lewis; Mutch, William James; Dickie, A.; Church, J.; Ross, I. S.; Clark, B. M.; Noble, D.

    In: Clinica Chimica Acta, Vol. 307, No. 1-2, 2001, p. 15-21.

    Research output: Contribution to journalArticle

    Croal, BL, Mutch, WJ, Dickie, A, Church, J, Ross, IS, Clark, BM & Noble, D 2001, 'The clinical application of a urine albumin:creatinine ratio point-of-care device', Clinica Chimica Acta, vol. 307, no. 1-2, pp. 15-21. https://doi.org/10.1016/S0009-8981(01)00450-8
    Croal, Bernard Lewis ; Mutch, William James ; Dickie, A. ; Church, J. ; Ross, I. S. ; Clark, B. M. ; Noble, D. / The clinical application of a urine albumin:creatinine ratio point-of-care device. In: Clinica Chimica Acta. 2001 ; Vol. 307, No. 1-2. pp. 15-21.
    @article{b88f09df783c4eb3a8f75f2cf4456841,
    title = "The clinical application of a urine albumin:creatinine ratio point-of-care device",
    abstract = "Introduction: Microalbuminuria is an accepted predictive marker for the early detection of renal disease and the identification of patients at high risk of developing complications of diabetes and hypertension. The Bayer Clinitek 50 is a urine chemistry point-of-care analyser for the semi-quantitative measurement of albumin and creatinine and calculation of albumin:creatinine ratio (ACR). Method: Urine samples were obtained from 252 consecutive patients attending a city center diabetic clinic, and from 40 patients on admission to the ICU. Albumin and creatinine measurements were carried out using the Clinitek 50 and by the central laboratory. Results: The Clinitek 50 results agreed with the central laboratory results in 89{\%} of the diabetic patient samples and 80{\%} of the ICU patient samples. Excluding samples defined as normal by the Clinitek 50 (ACR < 3.4 mg/mmol) would have resulted in an 80{\%} reduction in samples sent to the lab for further quantification. The average length of stay in the group of ICU patients with normal ACR was significantly less than for those patients with an abnormal ACR (p < 0.005). Conclusions: The Clinitek 50 provides useful, immediate clinical information regarding the microalbuminuria status for use in the diabetic clinic setting or as a potential immediate risk management tool in intensive care. (C) 2001 Elsevier Science B.V. All rights reserved.",
    keywords = "microalbuminuria, diabetes mellitus, intensive care, MICROALBUMINURIA, DISEASE",
    author = "Croal, {Bernard Lewis} and Mutch, {William James} and A. Dickie and J. Church and Ross, {I. S.} and Clark, {B. M.} and D. Noble",
    year = "2001",
    doi = "10.1016/S0009-8981(01)00450-8",
    language = "English",
    volume = "307",
    pages = "15--21",
    journal = "Clinica Chimica Acta",
    issn = "0009-8981",
    publisher = "Elsevier",
    number = "1-2",

    }

    TY - JOUR

    T1 - The clinical application of a urine albumin:creatinine ratio point-of-care device

    AU - Croal, Bernard Lewis

    AU - Mutch, William James

    AU - Dickie, A.

    AU - Church, J.

    AU - Ross, I. S.

    AU - Clark, B. M.

    AU - Noble, D.

    PY - 2001

    Y1 - 2001

    N2 - Introduction: Microalbuminuria is an accepted predictive marker for the early detection of renal disease and the identification of patients at high risk of developing complications of diabetes and hypertension. The Bayer Clinitek 50 is a urine chemistry point-of-care analyser for the semi-quantitative measurement of albumin and creatinine and calculation of albumin:creatinine ratio (ACR). Method: Urine samples were obtained from 252 consecutive patients attending a city center diabetic clinic, and from 40 patients on admission to the ICU. Albumin and creatinine measurements were carried out using the Clinitek 50 and by the central laboratory. Results: The Clinitek 50 results agreed with the central laboratory results in 89% of the diabetic patient samples and 80% of the ICU patient samples. Excluding samples defined as normal by the Clinitek 50 (ACR < 3.4 mg/mmol) would have resulted in an 80% reduction in samples sent to the lab for further quantification. The average length of stay in the group of ICU patients with normal ACR was significantly less than for those patients with an abnormal ACR (p < 0.005). Conclusions: The Clinitek 50 provides useful, immediate clinical information regarding the microalbuminuria status for use in the diabetic clinic setting or as a potential immediate risk management tool in intensive care. (C) 2001 Elsevier Science B.V. All rights reserved.

    AB - Introduction: Microalbuminuria is an accepted predictive marker for the early detection of renal disease and the identification of patients at high risk of developing complications of diabetes and hypertension. The Bayer Clinitek 50 is a urine chemistry point-of-care analyser for the semi-quantitative measurement of albumin and creatinine and calculation of albumin:creatinine ratio (ACR). Method: Urine samples were obtained from 252 consecutive patients attending a city center diabetic clinic, and from 40 patients on admission to the ICU. Albumin and creatinine measurements were carried out using the Clinitek 50 and by the central laboratory. Results: The Clinitek 50 results agreed with the central laboratory results in 89% of the diabetic patient samples and 80% of the ICU patient samples. Excluding samples defined as normal by the Clinitek 50 (ACR < 3.4 mg/mmol) would have resulted in an 80% reduction in samples sent to the lab for further quantification. The average length of stay in the group of ICU patients with normal ACR was significantly less than for those patients with an abnormal ACR (p < 0.005). Conclusions: The Clinitek 50 provides useful, immediate clinical information regarding the microalbuminuria status for use in the diabetic clinic setting or as a potential immediate risk management tool in intensive care. (C) 2001 Elsevier Science B.V. All rights reserved.

    KW - microalbuminuria

    KW - diabetes mellitus

    KW - intensive care

    KW - MICROALBUMINURIA

    KW - DISEASE

    U2 - 10.1016/S0009-8981(01)00450-8

    DO - 10.1016/S0009-8981(01)00450-8

    M3 - Article

    VL - 307

    SP - 15

    EP - 21

    JO - Clinica Chimica Acta

    JF - Clinica Chimica Acta

    SN - 0009-8981

    IS - 1-2

    ER -